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CLInICaL ImpLICatIon
Patients with primary immunodeficiency are at an increased risk of cancer. Our case and literature 
review indicate an association between X-linked agammaglobulinemia and gastrointestinal malig-
nancy and suggest that screening for gastrointestinal malignancy should occur for patients with 
X-linked agammaglobulinemia and gastrointestinal symptoms, unexplained anemia, or atrophic 
gastritis.
X-linked agammaglobulinemia (XLA) is an X-linked inherited disease caused by a germline 
mutation in the BTK gene leading to Bruton’s tyrosine kinase deficiency, which results in the impaired 
development of B-lymphocytes and a subsequent lack of immunoglobulin production. Patients with 
XLA have an increased susceptibility to bacterial and viral infections, and multiple case reports have 
been published regarding an association between XLA and gastrointestinal (GI) malignancy.
Here, we describe a case of a 25-year-old man with XLA and HIV, who developed gastric adeno-
carcinoma. Previously reported cases of XLA and GI malignancy are also reviewed and summarized.
Case RepoRt
A 25-year-old African-American man was referred to our center for continuous management of 
his XLA and HIV. At the age of 2 years, he started to develop recurrent infections, and based on a 
positive family history of XLA in a maternal uncle and several cousins, he was diagnosed with XLA 
and was started on intravenous immunoglobulin (IVIG) replacement since his diagnosis. Genetic 
testing was not initially done; however, recent genetic testing revealed a novel pathogenic variant 
in BTK c.307 C > T p.Gln103Ter (Q103X). His course was complicated by several sinopulmonary 
infections requiring hospitalization. Due to high-risk sexual behavior, he was screened for Human 
Immunodeficiency Virus (HIV) and at the age of 23 years and was found to be positive for HIV 
with high viral load; viral serology was never obtained due to his baseline agammaglobulinemia. He 
was asymptomatic and was started on, highly active antiretroviral therapy (HAART) (elvitegravir/
cobicistat/emtricitabine/tenofovir), which maintained his CD4 count >1000  cells/mm3 and an 
undetectable viral load.
At the age of 24  years, he developed recurrent Campylobacter jejuni bacteremia and cellulitis 
of the leg, which was treated with meropenem for 4 weeks, subsequent episode was treated with a 
combination of intravenous meropenem and amikacin for 6 weeks. Suppressive doxycycline therapy 
was recommended, but the patient declined. Despite high-dose IVIG (700 mg/kg every 3 weeks), 
he continued to have immunoglobulin (Ig)G troughs (400–560 mg/dL). His stool culture, ova and 
parasite microscopic examination, and Giardia PCR were negative.
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The patient had chronic iron-deficiency anemia and positive 
occult blood in his stool; therefore, an esophagogastroduoden-
oscopy (EGD) and colonoscopy were performed. His colonos-
copy with random biopsy was normal. However, EGD showed 
gastric inflammation with erosions and ulceration. A gastric 
biopsy showed poorly differentiated gastric adenocarcinoma, 
which was her2/neu negative. The stain for Helicobacter pylori 
was positive. From a clinical stand point, except for his recur-
rent cellulitis, the patient did not have any other symptoms 
such as abdominal pain, early satiety, or weight loss. His review 
of systems as well did not reveal any respiratory symptoms. 
Abdominal computed tomography (CT) was negative for 
enlarged lymph nodes. However, a 1.4-cm arterially enhancing 
lesion in the left hepatic lobe was detected using abdominal and 
pelvic CT, with at least two adjacent sub-centimeter enhancing 
foci and two hepatic lesions. Abdominal magnetic resonance 
imaging characterized the larger lesion as hemangioma and 
the smaller lesions as cysts. Chest CT showed a 5-mm nodule, 
thought to be a granuloma. However, repeat CT scan of the lower 
lungs did not identify any nodules. His lungs otherwise were 
clear with no evidence of bronchiectasis or any other interstitial 
process. Genetic testing for CDH1 gene mutations, which are 
associated with hereditary diffuse Gastric cancer, was negative. 
He underwent subtotal gastrectomy, lymphadenectomy, and 
Roux-en-Y gastrojejunostomy. His post-operative pathology 
showed moderately poor differentiation of the adenocarcinoma 
with a signet ring component that was primarily mucosal with 
focal submucosal invasion, 0/20 nodes, negative margins, and 
diffuse metaplasia as well as omentum negative. Staining was 
positive for H. pylori.
His final diagnosis was stage 1A gastric cancer. No further 
treatment was recommended, and he was placed under surveil-
lance with no evidence of malignant recurrence. However, he 
subsequently developed one episode of C. jejuni bacteremia that 
was treated with intravenous antibiotics.
Esophagogastroduodenoscopy was performed 1 year later and 
was negative for any ulcerations or concerning signs of recurrence.
DIsCUssIon
Patients infected with HIV are at increased risk of certain malig-
nancies, including breast, anal, cervical, lung, colorectal, prostate, 
and hepatocellular carcinoma (1). However, gastric cancer has not 
been reported to have increased prevalence among HIV-infected 
patients. Our patient did not have an acquired immune deficiency 
syndrome (AIDS)-defining clinical condition. On the other hand, 
patients with antibody deficiency are at greater risk of lymphoma 
and GI malignancy (2). The increased incidence of stomach 
cancer in patients with common variable immunodeficiency 
disorders could be related to the high frequency of achlorhydria.
In our literature review of GI malignancy and XLA, we found 
a total of 15 cases of GI malignancy (5 cases of gastric adenocarci-
noma, 9 cases of colorectal carcinoma, and 1 case of liver cancer) 
in addition to our reported case (Table 1).
The median age of male patients was 30  years (range, 
7–40 years), indicating early onset of GI malignancy in patients 
taBLe 1 | Review of the literature regarding patients with gastrointestinal (GI) malignancy and X-linked agammaglobulinemia.
Case Country presenting GI  
symptoms
Histology anemia IgG (mg/dL) 
on IVIG
solid tumor stage age 
(years)
outcome
Adachi et al. (3) Japan Diarrhea; frequent urge to 
defecate
NA NA 95 Colorectal Local 22 Alive
Sasi et al. (4) Saudi 
Arabia
Loss of appetite, weight 
loss, diarrhea, right-sided 
abdominal pain






France Vomiting, dysphagia Chronic atrophic 
gastritis, negative HP
NA 235–450 Gastric NA 26 NA
Staines Boone 
et al. (6)
Mexico Phlebitis of the right leg, 
weight loss
Gastric ulcer Megaloblastic 625 Gastric End 30 Dead
Brosens et al. (7) Netherlands Malabsorption, weight loss NA NA NA Colorectal Local 45 Alive
Brosens et al. (7) Netherlands Weight loss Positive HP NA NA Colorectal Local 37 Alive
Chisuwa et al. (8) Japan NA NA NA NA Colorectal NA NA NA
Kinlen et al. (2) UK NA NA NA NA Gastric End 25 Dead
Lackmann  
et al. (9)
Germany Sensory deficit in the left 
leg, B12 deficiency
Negative HP;  
atrophic gastritis
Megaloblastic 172 Gastric Early 15 Alive
Lavilla et al. (10) Spain Vomiting, diarrhea, weight 
loss
Atrophic gastritis Megaloblastic 479 Gastric Mets 23 Alive
Our case USA Cellulitis of the leg Positive HP NA 400–560 Gastric 1A 25 Alive
Vajdic et al. (11) Australia NA NA NA NA Gastric NA 45 NA
Van der Meer 
et al. (12)
Netherlands NA NA NA NA Colorectal NA 36 Dead
Van der Meer 
et al. (12)
Netherlands Abdominal distension, 
cramps, diarrhea
Villous atrophy Microcytic 600 Colorectal NA NA Dead
Van der Meer 
et al. (12)
Netherlands Diarrhea, abdominal 
cramps, weight loss
NA NA Undetectable Colorectal NA NA Dead
Van der Meer 
et al. (12)
Netherlands Diarrhea, abdominal 
cramps
NA NA NA Colorectal NA 36 Dead
IgG, immunoglobulin G; IVIG, intravenous immunoglobulin; HP, Helicobacter pylori.
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with XLA. In the general population, the average age at diagnosis 
is 69 years, according to the American Cancer Society, and more 
than 80% of diagnosed cases of colorectal cancer occur in patients 
older than 55 years, according to a US task force.
Our patient had C. jejuni bacteremia, gastric inflammation, 
and H. pylori infection. He continued to have low IgG levels 
despite increasing the IgG replacement dose and frequency. We 
looked for a similar pattern in previously reported cases. Nine of 
the 16 patients had IgG levels <700 mg/dL, and 6 of these patients 
had levels <500  mg/dL, despite IVIG replacement. Two of the 
reported cases were positive for H. pylori, two were positive for 
C. jejuni bacteremia, two were infected with Giardia lamblia, and 
a majority had chronic atrophic gastritis. We hypothesized that 
chronic gastritis, with or without H. pylori infection, results in 
chronic inflammation, which could increase IgG catabolism or 
GI losses.
The anemia and positive occult blood in the present patient 
prompted the GI workup that led to his diagnosis. Three of the 
previously reported patients had megaloblastic anemia, and one 
patient had microcytic anemia. Chronic gastric inflammation 
can lead to achlorhydria, which in turn leads to megaloblastic 
anemia; this might be linked with gastric carcinoma in patients 
with common variable immunodeficiency (2) or XLA (6).
Finally, we reviewed the literature for the presenting signs and 
symptoms that support a diagnosis of GI malignancy; 10 of the 16 
reported patients with XLA, who were diagnosed with GI malig-
nancy, presented with weight loss or abdominal complaints such 
as diarrhea, a frequent urge to defecate, abdominal distension, 
cramping, and vomiting, which likely initiated the GI workup 
and led to an early diagnosis of GI malignancy. While there are 
many intestinal complications of antibody deficiencies, this one 
should be kept on the differential owing to its potential severity 
and treatability.
In conclusion, our case and review of the previous literature 
indicate an increased risk of GI malignancy in patients with XLA. 
The fact that our patient was HIV infected could have increased 
his risk of malignancy in general, although medical literature 
does not suggest particularly increased the risk of gastric cancer 
among HIV-infected patients. We found the presence of H. pylori 
infection and megalobastic anemia to be associated with GI 
malignancy in XLA, and since those could be detected in non-
invasive ways (via urea breath test and B12 levels, respectively) we 
suggest screening for those factors in all patients with XLA and 
if present, this should prompt physicians to initiate a workup for 
GI malignancy in those patients.
Finally, we would like to note that our patient developed 
gastric cancer at the age of 23 years, Lackmann et al. described 
a 10-year-old boy with XLA and gastric cancer (9), and all cases 
summarized in Table 1 were below the age of 40 years, pointing 
out to the early onset of gastric cancer in this pediatric-onset 
disease, and that long-term follow-up for such patients raise 
the awareness about complications to be sought in this disease. 
Further studies to evaluate the cost-effectiveness of early 
screening for GI malignancy in patients with XLA might be 
warranted.
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